The Src–ZNRF1 axis controls TLR3 trafficking and interferon responses to limit lung barrier damage
Journal of Experimental Medicine · 07.08.2023 · 220 (8)
DOI: 10.1084/jem.20220727 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Experimental Medicine, online erschienen am 09.05.2023. Verfasst von You-Sheng Lin und 14 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Molecular Medicine, College of Medicine, National Taiwan University , Taipei, Taiwan. Hauptthemen laut MEDLINE: COVID-19, Interferon Type I. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Taiwan University, National Taiwan University Hospital, Academia Sinica.
Abstract (Originalsprache)
Type I interferons are important antiviral cytokines, but prolonged interferon production is detrimental to the host. The TLR3-driven immune response is crucial for mammalian antiviral immunity, and its intracellular localization determines induction of type I interferons; however, the mechanism terminating TLR3 signaling remains obscure. Here, we show that the E3 ubiquitin ligase ZNRF1 controls TLR3 sorting into multivesicular bodies/lysosomes to terminate signaling and type I interferon production. Mechanistically, c-Src kinase activated by TLR3 engagement phosphorylates ZNRF1 at tyrosine 103, which mediates K63-linked ubiquitination of TLR3 at lysine 813 and promotes TLR3 lysosomal trafficking and degradation. ZNRF1-deficient mice and cells are resistant to infection by encephalomyocarditis virus and SARS-CoV-2 because of enhanced type I interferon production. However, Znrf1−/− mice have exacerbated lung barrier damage triggered by antiviral immunity, leading to enhanced susceptibility to respiratory bacterial superinfections. Our study highlights the c-Src–ZNRF1 axis as a negative feedback mechanism controlling TLR3 trafficking and the termination of TLR3 signaling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Molecular Medicine, College of Medicine, National Taiwan University , Taipei, Taiwan.
- Department of Clinical Laboratory Sciences and Medical Biotechnology, College of Medicine, National Taiwan University, Taipei, Taiwan.
- Genomics Research Center, Academia Sinica , Taipei, Taiwan.
- Department of Pathology and Laboratory Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
- Immunology Research Center, National Health Research Institutes , Zhunan, Taiwan.
- Institute of Molecular Biology, Academia Sinica , Taipei, Taiwan.
ORCID-Profile: You-Sheng Lin, Yung-Chi Chang, Tai-Ling Chao, Ya-Min Tsai, Shu-Jhen Jhuang, Yu-Hsin Ho, Ting-Yu Lai, Yi-Ling Liu, Chiung-Ya Chen, Ching-Yen Tsai, Yi-Ping Hsueh, Sui-Yuan Chang, Tsung-Hsien Chuang, Chih-Yuan Lee, Li-Chung Hsu
Förderung
- National Taiwan University
- National Taiwan University Hospital
- Academia Sinica
- Ministry of Education
- National Science and Technology Council
- National Health Research Institutes
- Kaohsiung Veterans General Hospital
Zitieren
APA
Lin, Y. S., Chang, Y. C., Chao, T. L., Tsai, Y. M., Jhuang, S. J., Ho, Y. H., Lai, T. Y., Liu, Y. L., Chen, C. Y., Tsai, C. Y., Hsueh, Y. P., Chang, S. Y., Chuang, T. H., Lee, C. Y., & Hsu, L. C. (2023). The Src–ZNRF1 axis controls TLR3 trafficking and interferon responses to limit lung barrier damage. Journal of Experimental Medicine, 220(8). https://doi.org/10.1084/jem.20220727
Vancouver
Lin YS, Chang YC, Chao TL, Tsai YM, Jhuang SJ, Ho YH, et al. The Src–ZNRF1 axis controls TLR3 trafficking and interferon responses to limit lung barrier damage. Journal of Experimental Medicine. 2023;220(8). doi:10.1084/jem.20220727
BibTeX
@article{Lin2023,
author = {Lin, You-Sheng and Chang, Yung-Chi and Chao, Tai-Ling and Tsai, Ya-Min and Jhuang, Shu-Jhen and Ho, Yu-Hsin and Lai, Ting-Yu and Liu, Yi-Ling and Chen, Chiung-Ya and Tsai, Ching-Yen and Hsueh, Yi-Ping and Chang, Sui-Yuan and Chuang, Tsung-Hsien and Lee, Chih-Yuan and Hsu, Li-Chung},
title = {The Src–ZNRF1 axis controls TLR3 trafficking and interferon responses to limit lung barrier damage},
journal = {Journal of Experimental Medicine},
year = {2023},
volume = {220},
number = {8},
doi = {10.1084/jem.20220727}
}
EUVIMED